Skip to main content
OpenTrials
Completed

NCT Number: NCT00867295

Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device

This randomized trial is determining the role of antibiotic prophylaxis in the prevention of the infectious complications in patients carrying out totally implantable venous access device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Istanbul University Institute of Oncology

Istanbul, Capa, 34190, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 18 years of age
  • Have solid tumor
  • White cells >4000
  • Platelets >100.000
  • Prothrombin time in normal range

Exclusion criteria

  • Drug allergy
  • Diabetes mellitus

Treatment and study plan

cefazolin Sodium

Drug

cefazolin Sodium 1g i.v. before operation

Placebo

Drug

placebo

Primary outcomes

  1. infectious complication

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

Istanbul University

Other

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Trial to Determine Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device.

Acronym: TIVAD

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
Mar 23, 2009
Registry last updated
Jun 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.